Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...
ADVERTISEMENT ADVERTISEMENT Night Editor Israel has released its conclusions after an investigation into the return of four bodies by Hamas—claiming one of them is not who the terror group claims it ...
Genetic testing should be used to help doctors spot high-risk cases of myeloma and enable targeted treatments, say ...
Many patients with overweight or obesity discontinue glucagon-like peptide-1 receptor agonist therapy within one year.
Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.
Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...
GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.
GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.
Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
Medscape Medical News, November 14, 2024 GLP-1 Prescribing Decisions ... 2024 ATA 2024 Managing Long-Term Health Risks in Thyroid Cancer Survivors ATA 2024 spotlighted new research to help ...